Are Mounjaro and Zepbound still being made?
Yes, with expanded production capacity.
Did Eli Lilly stop making Mounjaro?
No.
Why do some people think tirzepatide is going away?
Confusion with the October 2024 shortage resolution and its effect on compounded availability.
Is there still a tirzepatide shortage?
No. The FDA resolved the shortage on October 2, 2024.
Will tirzepatide be discontinued?
Not in any foreseeable timeframe.
Can I still get a tirzepatide prescription in 2026?
Yes, brand or compounded (with documented clinical reason) through appropriate channels.
Is the patent expiring soon?
No. Patents extend into the 2030s.
What about new GLP-1 drugs replacing tirzepatide?
Investigational drugs are additions to the category, not replacements.
Does insurance still cover tirzepatide?
Coverage varies by plan and indication; LillyDirect self-pay is an alternative.
Related guides
- Is Semaglutide Going Away? The Brand vs Compounded Distinction in 2026
- Is Compounded Tirzepatide Going Away? What Actually Changed in October 2024
- Is Compounded Semaglutide Going Away? The February 2025 Decision Explained
- How to Access Affordable Tirzepatide in 2026: Brand vs Compounded Cost Breakdown
- Mounjaro Injection Price Equivalent: What You'll Actually Pay for Brand vs Compounded Tirzepatide in 2026
- Best Price Tirzepatide in 2026: Brand-Name vs Compounded Cost Breakdown
Sources
- FDA Drug Shortage List, October 2, 2024 resolution notice
- Eli Lilly press releases on manufacturing expansion, 2020-2025
- Jastreboff AM et al., "Tirzepatide Once Weekly for the Treatment of Obesity," NEJM, July 2022 (SURMOUNT-1)
- Mounjaro FDA prescribing information, May 2022 with subsequent updates
- Zepbound FDA prescribing information, November 2023 with subsequent updates
- FDA approval of Zepbound for obstructive sleep apnea, December 2024
- Outsourcing Facilities Association v. FDA ruling, March 5, 2025
- Eli Lilly LillyDirect platform announcement, January 2024
- Eli Lilly Q4 2025 manufacturing capacity disclosure, investor relations
- U.S. Patent and Trademark Office records on tirzepatide patents
- Federal Food, Drug, and Cosmetic Act Section 503A and 503B provisions
- Retatrutide Phase 3 trial registrations (clinicaltrials.gov)
- Orforglipron Phase 3 trial registrations (clinicaltrials.gov)
Footer disclaimers
Platform Disclaimer. FormBlends connects patients with licensed clinicians for evaluation and prescription of GLP-1 therapy. We do not manufacture medications or replace the prescriber-patient relationship. Eligibility and prescribing decisions are made by licensed clinicians.
See transparent compounded pricing
Review compounded GLP-1 pricing and what provider-reviewed care includes, with no surprises at checkout.
Try the Cost Calculator →Compounded Medication Notice. Compounded tirzepatide is prepared by 503A pharmacy partners for individual patients based on prescriber documentation. It is not FDA-approved and is not bioequivalent to brand Mounjaro or Zepbound in a regulatory sense. The SURMOUNT clinical trial data applies to brand product.
Results Disclaimer. Weight outcomes vary individually. SURMOUNT-1 reported a 22.5% mean weight loss at the 15 mg dose over 72 weeks. Your result will depend on dose, adherence, baseline weight, lifestyle, and individual response.
Trademark Notice. Mounjaro, Zepbound, SURMOUNT, and LillyDirect are trademarks or service marks of Eli Lilly and Company. FormBlends is not affiliated with Eli Lilly.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →